Search Results
Search for other papers by JA Baugh in
Google Scholar
PubMed
Search for other papers by SC Donnelly in
Google Scholar
PubMed
The diverse actions of macrophage migration inhibitory factor (MIF) within the immuno-neuroendocrine system are yet to be fully understood, but it is clear that MIF plays a pivotal role in the regulation of both the innate and adaptive immune response. An emerging body of data presently indicates that MIF's position within the cytokine cascade is to act in concert with glucocorticoids to control the 'set point' and magnitude of the immune and inflammatory response. In this article we will review the actions of MIF within the immune system and discuss the overlapping and contrasting aspects of MIF and glucocorticoid biology. In particular we will focus on the role of MIF within the immuno-neuroendocrine interface and suggest molecular mechanisms by which MIF may counter-regulate glucocorticoid function. Finally we will discuss emerging evidence that functional MIF gene-promoter polymorphisms render one susceptible to elevated MIF expression, and the development of an exaggerated immune/inflammatory response that potentiates the progression to chronic inflammatory disease.
Search for other papers by YO Lukyanenko in
Google Scholar
PubMed
Search for other papers by AM Carpenter in
Google Scholar
PubMed
Search for other papers by DE Brigham in
Google Scholar
PubMed
Search for other papers by DM Stocco in
Google Scholar
PubMed
Search for other papers by JC Hutson in
Google Scholar
PubMed
The purpose of this investigation was to study the mechanism of action of a macrophage-derived factor that stimulates steroid production by Leydig cells. This factor increased testosterone production within 30 min, and reached a half-maximal response by 6-8 h. At a maximal dose, it stimulated testosterone production 20-fold at 24 h. Its efficacy was consistently higher than that achieved with a maximal dose of human chorionic gonadotropin (hCG). However, Leydig cells treated with a maximal dose of both the macrophage-derived factor and hCG secreted the same amount of testosterone as when given a maximal dose of only the macrophage-derived factor. The macrophage-derived factor did not require new protein synthesis to stimulate testosterone production, nor did it alter the amount of steroidogenic acute regulatory protein (StAR). While the macrophage-derived factor required an active cholesterol side-chain cleavage complex system, it did not alter the capacity of this enzyme complex. Finally, the macrophage-derived factor was unable to stimulate the production of progesterone by isolated mitochondria. In summary, the macrophage-derived factor is a highly active, acute regulator of steroidogenesis that acts through a high capacity StAR-independent pathway.
Search for other papers by L Oziol in
Google Scholar
PubMed
Search for other papers by P Faure in
Google Scholar
PubMed
Search for other papers by N Bertrand in
Google Scholar
PubMed
Search for other papers by P Chomard in
Google Scholar
PubMed
Oxidized low density lipoproteins (LDL) are highly suspected of initiating the atherosclerosis process. Thyroid hormones and structural analogues have been reported to protect LDL from lipid peroxidation induced by Cu2+ or the free radical generator 2,2'-azobis-'2-amidinopropane' dihydrochloride in vitro. We have examined the effects of thyroid compounds on macrophage-induced LDL oxidation. Human monocyte-derived macrophages (differentiated U937 cells) were incubated for 24 h with LDL and different concentrations (0-20 microM) of 3,5,3'-triiodo-l -thyronine (T3), 3,5,3',5'-tetraiodo-L-thyronine (T4), 3,3',5'-tri-iodo-l -thyronine (rT3), the T3 acetic derivative (3,5,3'-tri-iodothyroacetic acid; TA3) or L-thyronine (T0) (experiment 1). Cells were also preincubated for 24 h with 1 or 10 microM of the compounds, washed twice, then incubated again for 24 h with LDL (experiment 2). Oxidation was evaluated by measurement of thiobarbituric acid-reactive substances (TBARS) and cell viability by lactate deshydrogenase release. In experiment 1, T0 had no effect, whereas the other compounds decreased LDL TBARS production, but T3 and TA3 were less active than T4 and rT3 (IC50: 11.0 +/- 2.6 and 8.1 +/- 0.8 vs 1.4 +/- 0.5 and 0.9 +/- 0.3 microM respectively). In experiment 2, the compounds at 1 microM had no effect; at 10 microM, T3 and rT3 slightly reduced LDL TBARS production, whereas TA3 and T4 inhibited it by about 50% and 70% respectively. TBARS released by the cells were also highly decreased by T3, T4, rT3 and TA3 in experiment 1, but only by T3 (30%) and T4 (70%) in experiment 2. Cell viability was not affected by the compounds except slightly by TA3 at 10 microM. The data suggested that the physico-chemical antioxidant capacity of thyroid compounds was modulated by their action on the intracellular redox systems of macrophage. Overall cellular effects of T3 led to a reduction of its antioxidant capacity whereas those of T4 increased it. Thus T4 might protect LDL against cellular oxidation in vivo more than T3.
Search for other papers by ME Pyle in
Google Scholar
PubMed
Search for other papers by M Korbonits in
Google Scholar
PubMed
Search for other papers by M Gueorguiev in
Google Scholar
PubMed
Search for other papers by S Jordan in
Google Scholar
PubMed
Search for other papers by B Kola in
Google Scholar
PubMed
Search for other papers by DG Morris in
Google Scholar
PubMed
Search for other papers by A Meinhardt in
Google Scholar
PubMed
Search for other papers by MP Powell in
Google Scholar
PubMed
Search for other papers by FX Claret in
Google Scholar
PubMed
Search for other papers by Q Zhang in
Google Scholar
PubMed
Search for other papers by C Metz in
Google Scholar
PubMed
Search for other papers by R Bucala in
Google Scholar
PubMed
Search for other papers by AB Grossman in
Google Scholar
PubMed
Macrophage migration inhibitory factor (MIF) is an essential regulator of the macrophage responses to endotoxin. MIF also has the ability to override the anti-inflammatory actions of glucocorticoids during an immune response, and is thus an important pro-inflammatory factor. The presence of MIF in cells of the anterior pituitary has been described, and high levels of MIF in other rapidly proliferating tIssues have also been demonstrated. It has been hypothesised that MIF release from these cells is influenced by the hypothalamo-pituitary-adrenal axis, and that ACTH and MIF are released simultaneously to exert counter-regulatory effects on cortisol. However, another intracellular role for MIF has also been suggested as it has been shown that MIF exerts an effect on the inhibitory cell cycle control protein p27 through an interaction with Jab1, a protein implicated in p27 degradation. We studied MIF expression in different normal and adenomatous human pituitary samples using immunohistochemistry and RT-PCR. There was evidence of co-immunoprecipitation of MIF with Jab1, suggesting an interaction of the two proteins. Our results showed that there is increased expression of MIF protein in the nuclei of all pituitary adenomas compared with normal tIssue (P=0.0067), but there was no statistically significant difference in nuclear MIF expression between the different adenoma types. Nuclear MIF expression correlated positively with p27 and its phosphorylated form in normal tIssue (P=0.0028 and P<0.0001); however, this relationship was not seen in the adenoma samples. Cytoplasmic expression of MIF was found to be variable both in normal and adenomatous samples, with no consistent pattern. MIF mRNA was demonstrated to be present in all tumour and normal samples studied. Somatotroph tumours showed higher MIF mRNA expression compared with normal pituitary or other types of adenomas. In conclusion, MIF is expressed in cell nuclei in pituitary adenomas to a greater extent than in normal pituitary tIssue. We speculate that it may play a role in the control of the cell cycle, but whether its higher level in adenomas is a cause or a consequence of the tumorigenic process remains to be clarified.
Search for other papers by RP Donn in
Google Scholar
PubMed
Search for other papers by DW Ray in
Google Scholar
PubMed
The immunological and neuroendocrine properties of macrophage migration inhibitory factor (MIF) are diverse. In this article we review the known cellular, molecular and genetic properties of MIF that place it as a key regulatory cytokine, acting within both the innate and adaptive immune responses.The unexpected and paradoxical induction of MIF secretion by low concentrations of glucocorticoids is explored. The role of MIF as a locally acting modulator of glucocorticoid sensitivity within foci of inflammation is also discussed. MIF has no homology with any other pro-inflammatory cytokine and until recently lacked a recognised transmembrane receptor. MIF has also been shown to be directly taken up into target cells and to interact with intracellular signalling molecules, including the Jun activation domain-binding protein Jab-1.Comprehensive analysis of the MIF gene has identified important functional polymorphisms and a series of genetic studies has revealed both association and linkage of MIF with inflammatory diseases. Altered MIF regulation may therefore be pivotal to acquiring chronic inflammation following an innate immune response.
Search for other papers by SJ Heasman in
Google Scholar
PubMed
Search for other papers by KM Giles in
Google Scholar
PubMed
Search for other papers by C Ward in
Google Scholar
PubMed
Search for other papers by AG Rossi in
Google Scholar
PubMed
Search for other papers by C Haslett in
Google Scholar
PubMed
Search for other papers by I Dransfield in
Google Scholar
PubMed
Glucocorticoids represent one of the most effective clinical treatments for a range of inflammatory conditions, including severe acute inflammation. Although glucocorticoids are known to affect processes involved in the initiation of inflammation, the influence of glucocorticoids on the mechanisms by which acute inflammation normally resolves have received less attention. Apoptosis of granulocytes present at inflamed sites leads to their rapid recognition and internalisation by macrophages, a process which may be important for resolution of inflammation. However, if clearance of either eosinophils or neutrophils is impaired, these cells rapidly undergo secondary necrosis leading to release of pro-inflammatory mediators from the phagocyte, potentially prolonging inflammatory responses. Physiologically relevant concentrations of glucocorticoids accelerate eosinophil apoptosis whilst delaying neutrophil apoptosis during in vitro culture. Here we discuss key pathways regulating the granulocyte apoptotic programme and summarise the effects of glucocorticoids on monocyte differentiation and the consequent changes to apoptotic cell clearance capacity. Definition of the mechanisms underlying resolution of inflammatory responses following glucocorticoid treatment may unveil new targets for modulation of inflammatory disease, allowing co-ordinated augmentation of granulocyte apoptosis together with increased macrophage capacity for clearance of apoptotic cells.
Search for other papers by Qiongge Zhang in
Google Scholar
PubMed
Search for other papers by Chaoqun Wang in
Google Scholar
PubMed
Search for other papers by Yehua Tang in
Google Scholar
PubMed
Search for other papers by Qiangqiang Zhu in
Google Scholar
PubMed
Search for other papers by Yongcheng Li in
Google Scholar
PubMed
Search for other papers by Haiyan Chen in
Google Scholar
PubMed
Search for other papers by Yi Bao in
Google Scholar
PubMed
Search for other papers by Song Xue in
Google Scholar
PubMed
Search for other papers by Liangliang Sun in
Google Scholar
PubMed
Search for other papers by Wei Tang in
Google Scholar
PubMed
Search for other papers by Xiangfang Chen in
Google Scholar
PubMed
Search for other papers by Yongquan Shi in
Google Scholar
PubMed
Search for other papers by Lefeng Qu in
Google Scholar
PubMed
Search for other papers by Bin Lu in
Google Scholar
PubMed
Search for other papers by Jiaoyang Zheng in
Google Scholar
PubMed
recognized as a proinflammatory and pro-atherogenic cytokine ( Cho et al. 2009 , Wolak 2014 ). In the progress of atherosclerosis, OPN have been shown to be highly expressed in macrophages, vascular smooth muscle cells (VSMCs) and endothelial cells (ECs
Search for other papers by L E Nicol in
Google Scholar
PubMed
Search for other papers by W R Grant in
Google Scholar
PubMed
Search for other papers by S M Comstock in
Google Scholar
PubMed
Search for other papers by M L Nguyen in
Google Scholar
PubMed
Search for other papers by M S Smith in
Google Scholar
PubMed
Search for other papers by K L Grove in
Google Scholar
PubMed
Pediatrics, Division of Neurosciences, Pape Pediatric Research Institute
Search for other papers by D L Marks in
Google Scholar
PubMed
Search for other papers by CK Glass in
Google Scholar
PubMed
Search for other papers by Monisha Rajasekaran in
Google Scholar
PubMed
Search for other papers by Ok-Joo Sul in
Google Scholar
PubMed
Search for other papers by Eun-Kyung Choi in
Google Scholar
PubMed
Search for other papers by Ji-Eun Kim in
Google Scholar
PubMed
Search for other papers by Jae-Hee Suh in
Google Scholar
PubMed
Search for other papers by Hye-Seon Choi in
Google Scholar
PubMed
act in an adipocyte-autonomous way, whereas others are mediated by macrophage polarization. Macrophages can obtain distinct functional phenotypes, M1 and M2, via different polarization responses to environmental stimuli. M1 phenotypes are stimulated
